Gurpreet Lamba
Hematology & Oncology · Burlington, VTNPI 1427294271
Payments from drug & device makers
Across 1,210 payments — averaging $55.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cornerstone Specialty Network LLC$12K
- AstraZeneca$9K
- Avyxa Pharma, LLC$4K
- Beigene USA, Inc.$3K
- Eisai Inc.$3K
- AbbVie$3K
- plus $33K from 54 others
What the payments were for
- Consulting fees$25,79839%
- Speaking & faculty fees$16,83825%
- Travel & lodging$4,6507%
- Food & beverage$18,97428%
- Education$5061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology & oncology providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 15 | $534,979 |
| CalquenceAcalabrutinib Maleate | 22 | $338,605 |
| JakafiRuxolitinib Phosphate | 12 | $194,587 |
| BrukinsaZanubrutinib | 13 | $192,046 |
| EliquisApixaban | 116 | $152,268 |
| Imatinib Mesylate | 11 | $30,035 |
| XareltoRivaroxaban | 21 | $25,227 |
| Enoxaparin Sodium | 11 | $11,570 |
| Ondansetron OdtOndansetron | 89 | $2,343 |
| Prochlorperazine Maleate | 68 | $1,067 |
| Omeprazole | 91 | $991 |
| Dexamethasone | 39 | $942 |
| Acyclovir | 41 | $938 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 23 | $748 |
| Gabapentin | 34 | $742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $191 | $534,97915 claims |
| AstraZenecaCalquence | $8,810 | $338,60522 claims |
| Incyte CorporationJakafi | $568 | $194,58712 claims |
| Beigene USA, Inc.Brukinsa | $3,066 | $192,04613 claims |
| PfizerEliquis | $1,176 | $152,268116 claims |
| Johnson & JohnsonXarelto | $762 | $25,22721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Vermonton file to place this against a meaningful peer group, so we don't.
Other hematology & oncology in Burlington
- Steven AdesBurlington$1.1M
- Farrah KhanBurlington$542K
- Rohit SinghBurlington$154K
- Hibba Tul RehmanBurlington$106K
- Diego Adrianzen HerreraBurlington$36K
- Paul UngerBurlington$12K
- Sakshi JasraBurlington$4K
- Maura BarryBurlington$58
- Chris HolmesBurlington$37
- Neil ZakaiBurlington$11
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.